Cargando…

Cluster phenotypes in a non-idiopathic pulmonary fibrosis fibrotic interstitial lung diseases cohort in Singapore

BACKGROUND: Non-idiopathic pulmonary fibrosis fibrosing interstitial lung diseases (F-ILDs) may demonstrate a progressive disease trajectory similar to idiopathic pulmonary fibrosis (IPF). We aimed to identify novel F-ILD phenotypes in a multi-ethnic South-East Asian population. METHODS: F-ILD subje...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kam, Michelle Li Wei, Tiew, Pei Yee, Chai, Hui Zhong, Low, Su Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344411/ https://www.ncbi.nlm.nih.gov/pubmed/35928611 http://dx.doi.org/10.21037/jtd-22-40

Ejemplares similares

Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
por: Takei, Reoto, et al.
Publicado: (2023)

Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
por: Keow, Jonathan, et al.
Publicado: (2022)

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
por: Feng, Haoshen, et al.
Publicado: (2020)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment
por: Cilli, Aykut, et al.
Publicado: (2023)

Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis
por: Epstein Shochet, Gali, et al.
Publicado: (2021)

Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic interstitial pneumonias
por: Higo, Hisao, et al.
Publicado: (2022)

Effects of pulmonary rehabilitation on daily life physical activity of fibrotic idiopathic interstitial pneumonia patients
por: Wallaert, Benoit, et al.
Publicado: (2018)

Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias
por: Wallaert, Benoit, et al.
Publicado: (2019)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
por: Dempsey, Timothy M., et al.
Publicado: (2022)

Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
por: Astor, Todd L., et al.
Publicado: (2023)

Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia
por: Fingerlin, Tasha E., et al.
Publicado: (2016)

Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
por: Hostettler, Katrin E, et al.
Publicado: (2014)

Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study
por: Wu, Wen-Jui, et al.
Publicado: (2022)

The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype
por: Olson, Amy L., et al.
Publicado: (2018)

Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
por: Samarelli, Anna Valeria, et al.
Publicado: (2021)

Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis
por: Enomoto, Noriyuki, et al.
Publicado: (2020)

Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
por: Khor, Yet H., et al.
Publicado: (2020)

Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis
por: Lee, Cathryn T., et al.
Publicado: (2022)

A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
por: Roach, Katy M., et al.
Publicado: (2018)

Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
por: Amati, Francesco, et al.
Publicado: (2022)

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
por: De Biasi, Sara, et al.
Publicado: (2015)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

CT Analysis of the Anterior Mediastinum in Idiopathic Pulmonary Fibrosis and Nonspecific Interstitial Pneumonia
por: Lee, Chang Hyun, et al.
Publicado: (2006)

Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?
por: Dhooria, Sahajal, et al.
Publicado: (2015)

Validation of the King’s Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis
por: Prior, Thomas Skovhus, et al.
Publicado: (2019)

Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease
por: Harari, Sergio
Publicado: (2018)

Non-coding RNA in idiopathic interstitial pneumonia and Covid-19 pulmonary fibrosis
por: Ali, Mohammad Shadab, et al.
Publicado: (2022)

Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
por: Zhang, David, et al.
Publicado: (2023)

Predicting clinical outcome with phenotypic clusters using quantitative CT fibrosis and emphysema features in patients with idiopathic pulmonary fibrosis
por: Bak, So Hyeon, et al.
Publicado: (2019)

Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis
por: Lee, Sang Hoon, et al.
Publicado: (2019)

Clinical impact of high-attenuation and cystic areas on computed tomography in fibrotic idiopathic interstitial pneumonias
por: Tanizawa, Kiminobu, et al.
Publicado: (2015)

Acute exacerbation of idiopathic pulmonary fibrosis: usual interstitial pneumonitis vs. possible usual interstitial pneumonitis pattern
por: Cao, Meng-Shu, et al.
Publicado: (2019)

Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020)

Antigen avoidance and environmental inhalation challenge for successful diagnosis of fibrotic hypersensitivity pneumonitis mimicking idiopathic pulmonary fibrosis
por: Ito, Yasuhiro, et al.
Publicado: (2022)

Bronchoalveolar Lavage Cell Count and Lymphocytosis Are the Important Discriminators between Fibrotic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis
por: Sobiecka, Małgorzata, et al.
Publicado: (2023)

Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes
por: Sauleda, Jaume, et al.
Publicado: (2018)

The In Vivo Fibrotic Role of FIZZ1 in Pulmonary Fibrosis
por: Liu, Tianju, et al.
Publicado: (2014)

Progressive fibrotic interstitial lung disease
por: Pereira, Carlos A C, et al.
Publicado: (2023)

A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease
por: Wong, Alyson W., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c04qe9inoiss3d581u1rtrpri0